Overview


Antimetabolites are chemotherapy drugs used to treat cancer cells from replicating. Chemotherapy is a common cancer treatment that sends drugs through your bloodstream to kill cancer cells and prevent tumor growth. They trick cancer cells into using the drug instead of the molecules it needs to make the genetic material to replicate or DNA. There are different classes of chemotherapy drugs — including antimetabolites, alkylating agents, and topoisomerase inhibitors, among others. Various classes of chemotherapy drugs have different mechanisms of action. This means that each class works differently in the body to destroy cancer cells. Antimetabolites are generally used to treat leukemias and cancers of the breast, ovary, and intestinal tract. However, since the drugs work to restrict the growth of any fast-dividing cell type, they also can be used to treat various other cancers.

Different antimetabolite drugs are taken in different ways based on the drug and the type of cancer being treated. Some antimetabolites are available as tablets or liquids that are taken by mouth every day. Others are given by injection through an intravenous (IV) line that a health care professional inserts into a vein. Often, it’s a specific kind of IV line called a mediport that sits in a large, central vein. Each drug includes specific instructions about how it should be administered.

FutureWise Market Research has published a report that provides an insightful analysis antimetabolite drug market trends that are affecting the overall market growth. This report will provide a detailed analysis of market share, regional insights, and competitor analysis that includes stature of key manufacturers operational in this industry. According to the analysis conducted by FutureWise research analysts, antimetabolite drug market is estimated to register a considerable growth rate over the forecast period. This report lists the market segments and potential prospects available across this industry, in addition providing crucial information on the total valuation currently held by the industry. Moreover, this report will assist key management individuals in an organisation to enhance their decisions pertaining to business expansion as well as strategic changes for increasing customer base.

  • Parenteral Medicines
  • Bristol-Myers Squibb
  • MerckCo.
  • Fresenius Kabi Oncology Limited
  • GlaxoSmithKline plc.
  • Cadila Pharmaceuticals
  • elgene
  • Celon Laboratories Pvt. Ltd.
  • Sanofi
  • Eli Lilly and Company
  • Novartis
  • Teva Pharmaceutical

(Note: The list of the major players will be updated with the latest market scenario and trends)

The rising incidence of types of cancer serves as a major driver for the growing demand for antimetabolite drugs. As the global population ages and environmental factors contribute to increased cancer rates, the demand for effective treatments becomes more critical. Antimetabolite drugs, known for disrupting cancer cell replication and growth, play a vital role in chemotherapy. Consequently, pharmaceutical firms and researchers are encouraged to develop and refine these drugs to satisfy the rising need for advanced and targeted cancer therapies. Also, this strengthened focus on innovation and development further boosts the product offerings in the market for antimetabolite drugs. Moreover, the use of antimetabolite drugs like Methotrexate in arthritis therapeutics comprises a key driver in the domain. Especially, Methotrexate, categorized as an antimetabolite, exerts its effects by interfering with the proliferation of cancer cells and dampening the immune response. In rheumatoid arthritis, early treatment with assertive therapies, such as Methotrexate, holds tremendous promise. By initiating treatment promptly, the progression of joint damage may be significantly reduced, eventually preserving crucial joint function. This approach relieves pain and inflammation and offers substantial potential for enhancing patients' overall quality of life. However, the high expenditure for developing novel drugs and factors such as extensive investments in rigorous research endeavors and comprehensive clinical trials may restrain the growth of the target market. These stages demand significant resources for laboratory studies, pre-clinical testing, and human trials to assure safety and effectiveness. Also, regulatory compliance, quality control, and fulfilling stringent government measures further hinder the market growth over the forecast period.

By Drug Class

  • Pyrimidine Compounds
  • Purine Compounds
  • Folate Antagonists
  • Demethylation Agents

By Route of Administration

  • Oral
  • Intravenous
  • Intramuscular

By Application

  • Cancer Therapeutic
  • Cardiac Therapeutic
  • Arthritis Therapeutic

By Distribution Channel

  • Retail Sales
  • Hospital Pharmacies
  • Retail Pharmacies
  • Drug Stores
  • Online Pharmacies

By Region

  • North America
  • Europe
  • Asia-Pacific
  • Latin America
  • Middle East and Africa

This market research report also emphasis on factors affecting the growth rate in various regions listed above. A deep-down analysis of region will also be provided in the final version of this market which is based on conclusion of primary interviews and secondary data point gathered during the process.

By region, the market is segmented into North America, Latin America, Europe, Asia-Pacific, and Middle East & Africa. North America registered highest share in the market in 2022. Owing to the increasing research on cancer therapeutics, rising prevalence of chronic diseases like cancer, well-established research infrastructure, government-supported funding policies, rise in the cases of arrhythmic diseases, and advancements in medical technologies in the region are expected to propel the demand for antimetabolite drugs market. In addition, the presence of key players, rising levels of disposable income, favorable reimbursement policies for patients, high demand for advanced treatment methods, product launches, and developed healthcare infrastructure in the area. Therefore, the above-mentioned factors are projected to drive the target market over the forecast period.

  • Tier 1 players- established companies in the market with a major market share
  • Tier 2 players
  • Emerging players which are growing rapidly
  • New Entrants

  • Growth prospects
  • SWOT analysis
  • Key trends
  • Key data-points affecting market growth

  • To provide with an exhaustive analysis on the Antimetabolite Drug Market By Drug Class, By Route of Administration, By Application, By Distribution Channel and By Region.
  • To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints)
  • To evaluate and forecast micro-markets and the overall market
  • To predict the market size, in key regions— North America, Europe, Asia Pacific, Latin America and Middle East and Africa.
  • To record and evaluate competitive landscape mapping- product launches, technological advancements, mergers and expansions

  • We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement
  • The customization Mobility Care offered are free of charge with purchase of any license of the report
  • You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com

Table of Contents


  • 1.   Market Introduction
    •   1. Objectives of the Study
        2. Market Definition
        3. Market Scope
         3.1. Years Considered for the Study
         3.2. Market Covered
        4. Currency
        5. Limitations
        6. Stakeholders
  • 2.   Research Methodology
    •   1. Research Data
         1.1. Secondary Data
          1.1.1. Key Data from Secondary Sources
         1.2. Primary Data
          1.2.1. Key Data from Primary Sources
        2. Market Size Estimation
        3. Market Breakdown and Data Triangulation
        4. Assumptions for the Study
  • 3.   Executive Summary
    •   1. Market Outlook
        2. Segment Outlook
        3. Competitive Insights
  • 4.   Global Antimetabolite Drug Market Variables, Trends and Scope
    •   1. Market Lineage Outlook
        2. Penetration and Growth Prospect Mapping
        3. Industry Value Chain Analysis
        4. Cost Analysis Breakdown
        5. Technology Overview
        6. Regulatory Framework
         6.1. Reimbursement Framework
         6.2. Standards and Compliances

  • 5.   Market Overview
    •   1. Market Dynamics
         1.1. Market Driver Analysis
          1.1.1. Increasing focus of Antimetabolite Drug Market Companies on Brand Protection
          1.1.2. Untapped Opportunities in Emerging Regions
         1.2. Market Restraint Analysis
          1.2.1. High Cost Associated with Implementation of Predictive Analysis
         1.3. Industry Challenges
          1.3.1. Presence of Ambiguous Regulatory Framework
  • 6.   Global Antimetabolite Drug Market Analysis Tools
    •   1. Industry Analysis - Porter’s
         1.1. Supplier Power
         1.2. Buyer Power
         1.3. Substitution Threat
         1.4. Threat from New Entrants
         1.5. Competitive Rivalry
        2. Pestel Analysis
         2.1. Political Landscape
         2.2. Environmental Landscape
         2.3. Social Landscape
         2.4. Technology Landscape
         2.5. Legal Landscape
        3. Major Deals And Strategic Alliances Analysis
         3.1. Joint Ventures
         3.2. Mergers and Acquisitions
         3.3. Licensing and Partnership
         3.4. Technology Collaborations
         3.5. Strategic Divestments
        4. Market Entry Strategies
        5. Case Studies
  • 7.   Global Antimetabolite Drug Market, By Drug Class Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Pyrimidine Compounds
        2. Purine Compounds
        3. Folate Antagonists
        4. Demethylation Agents

  • 8.   Global Antimetabolite Drug Market, By Route of Administration Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Oral
        2. Intravenous
        3. Intramuscular

  • 9.   Global Antimetabolite Drug Market, By Application Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Cancer Therapeutic
        2. Cardiac Therapeutic
        3. Arthritis Therapeutic

  • 10.   Global Antimetabolite Drug Market, By Distribution Channel Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Retail Sales
        2. Hospital Pharmacies
        3. Retail Pharmacies
        4. Drug Stores
        5. Online Pharmacies

  • 11.   North America Antimetabolite Drug Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. U.S.A
         2.2. Canada
         2.3. Mexico
        3. Market Size (USD Million) Forecast for North America 2023-2031

  • 12.   Latin America Antimetabolite Drug Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Brazil
         2.2. Venezuela
         2.3. Argentina
         2.4. Rest of Latin America
        3. Market Size (USD Million) Forecast for Latin America 2023-2031

  • 13.   Europe Antimetabolite Drug Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Germany
         2.2. U.K
         2.3. France
         2.4. Italy
         2.5. Spain
         2.6. Russia
         2.7. Poland
         2.8. Rest of Europe
        3. Market Size (USD Million) Forecast for Europe 2023-2031

  • 14.   Asia Pacific Antimetabolite Drug Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Japan
         2.2. China
         2.3. India
         2.4. Australia and New Zealand
         2.5. ASEAN
         2.6. Rest of Asia Pacific
        3. Market Size (USD Million) Forecast for Asia Pacific 2023-2031

  • 15.   Middle East and Africa Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Saudi Arabia
         2.2. UAE
         2.3. South Africa
         2.4. Egypt
        3. Market Size (USD Million) Forecast for MEA 2023-2031

  • 16.   Market Share Analysis and Competitive Landscape
    •   1. Global Landscape - Key Players, Revenue and Presence
        2. Global Share Analysis - Key Players (Tier 1, Tier 2, Tier 3)
        3. Global Emerging Companies
        4. North America - Market Share Analysis and Key Regional Players
        5. Europe - Market Share Analysis and Key Regional Players
        6. Asia Pacific - Market Share Analysis and Key Regional Players
        7. Global Key Player - Growth Matrix
  • 17.   Company Profiles (Competition Dashboard, Competitors Deep Dive, Products Offered and Financial Layouts)
    •   1. Parenteral Medicines
         1.1. Company Overview
         1.2. Product Portfolio
         1.3. SWOT Analysis
         1.4. Financial Overview
         1.5. Strategic Overview
        2. Bristol-Myers Squibb
         2.1. Company Overview
         2.2. Product Portfolio
         2.3. SWOT Analysis
         2.4. Financial Overview
         2.5. Strategic Overview
        3. MerckCo.
         3.1. Company Overview
         3.2. Product Portfolio
         3.3. SWOT Analysis
         3.4. Financial Overview
         3.5. Strategic Overview
        4. Fresenius Kabi Oncology Limited
         4.1. Company Overview
         4.2. Product Portfolio
         4.3. SWOT Analysis
         4.4. Financial Overview
         4.5. Strategic Overview
        5. GlaxoSmithKline plc.
         5.1. Company Overview
         5.2. Product Portfolio
         5.3. SWOT Analysis
         5.4. Financial Overview
         5.5. Strategic Overview
        6. Cadila Pharmaceuticals
         6.1. Company Overview
         6.2. Product Portfolio
         6.3. SWOT Analysis
         6.4. Financial Overview
         6.5. Strategic Overview
        7. elgene
         7.1. Company Overview
         7.2. Product Portfolio
         7.3. SWOT Analysis
         7.4. Financial Overview
         7.5. Strategic Overview
        8. Celon Laboratories Pvt. Ltd.
         8.1. Company Overview
         8.2. Product Portfolio
         8.3. SWOT Analysis
         8.4. Financial Overview
         8.5. Strategic Overview
        9. Sanofi
         9.1. Company Overview
         9.2. Product Portfolio
         9.3. SWOT Analysis
         9.4. Financial Overview
         9.5. Strategic Overview
        10. Eli Lilly and Company
         10.1. Company Overview
         10.2. Product Portfolio
         10.3. SWOT Analysis
         10.4. Financial Overview
         10.5. Strategic Overview
        11. Novartis
         11.1. Company Overview
         11.2. Product Portfolio
         11.3. SWOT Analysis
         11.4. Financial Overview
         11.5. Strategic Overview
        12. Teva Pharmaceutical
         12.1. Company Overview
         12.2. Product Portfolio
         12.3. SWOT Analysis
         12.4. Financial Overview
         12.5. Strategic Overview

  • 18.   Pre and Post COVID-19 Impact
    •   1. Positive influence on the healthcare industry
        2. The financial disruption of the manufacturing sector
        3. Impact of COVID-19 on emerging companies
        4. Significant mandates in the healthcare regulations initiated by administrations
        5. The overall economic slowdown of the developing and developed nations
  • 19.   FutureWise SME Key Takeaway Points for Client
Partner

Our Clients